CYP1A2＊1F基因多态性与肺癌术后化疗疗效及预后的关系  

Study on the Correlation Between CYP1A2 ＊ 1F Gene Polymorphism and the Efficacy of Postopera- tive Chemotherapy and Prognosis in Patients with Lung Cancer

作　　者：黎伟文[1] 

机构地区：[1]广东省中山市中医院化疗科,广东中山528400

出　　处：《医学临床研究》2017年第5期909-911,共3页Journal of Clinical Research

摘　　要：【目的】探讨细胞色素P4501A2（CYP1A2）＊1F基因多态性与肺癌术后化疗疗效及预后的关系。【方法】对100例肺癌患者进行CYP1A2基因多态性检查，分析CYP1A2＊1F与肺癌术后化疗效果及预后的相关性。【结果】①100例患者，部分缓解24例，稳定44例，临床获益率为68．00％，患者CYP1A2＊1F基因型以A／A型（49．00％）为主，其次为A／C型（38．00％）；②临床荻益患者中A／A基因型所占比例略高于未获益患者，但差异无显著性（P〉0．05）；③携带CYP1A2＊IFA／A基因型患者总生存时间略高于A／C型、C／C型，但各组之间相比较差异无显著性（P〉0．05）。【结论】CYP1A2＊IF突变基因型与肺癌术后化疗效果及预后无明显相关性。[Objective]To investigate the relationship between cytochrome P4501A2 （CYP1A2） ＊ 1F gene polymorphism and chemotherapy efficacy and prognosis in patients with lung cancer after operation. [Methods] CYP1A2 gene polymorphism was detected in 100 patients with lung cancer to analyze the correlation between CYP1A2 ＊ 1F and chemotherapy effect and prognosis of lung cancer after operation.[Results]In the 100 patients, partial remission were found in 24 cases, 44 cases were stable, the clinical benefit rate was 68%. The genotype of patients with CYP1A2 ＊ 1F was A/A mostly （49%）, followed by A/C （38 %）;The proportion of A/A genotype in patients with clinical benefit was slightly higher than that in patients without benefit, but the difference was not significant （ P 〉0.05）; The total survival time of patients with CYP1A2 ＊ iF A/A genotype was slightly higher than those of type A/C and type C/C, but there was no significant difference between the groups （ P 〉0.05）. [Conclusion] There is no significant correlation between CYP1A2 ＊ 1F mutation genotype and the efficacy of post- operative chemotherapy and prognosis in patients with lung cancer.

关 键 词：细胞色素P450 CYP1A2/遗传学 多态现象 遗传 肺肿瘤/外科学 肺肿瘤/药物疗法 预后 

分 类 号：R734.2[医药卫生—肿瘤]